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Introduction: Anemia is one o f  the most important consequences o f  chronic kidney disease. 
It is caused by a defect in erythropoietin regulation. Anemia can have an early onset, but the 
severity ant the prevalence increases with the progression the kidney disease.
Purpose and Objective: To do a complex examination o f  the treatment o f  anemia in 
Republic o f  M oldova and the efficacy o f  the methods used in the hemodialysis departments.
Materials and Methods: This is a retrospective study, analyzing the patient documentation 
o f  47 patients from the department o f  Nephrology and Hemodialysis o f  the Municipal Hospital “St. 
Trinity” and from the department o f  Hemodialysis o f  the Republican Clinical Hospital.
Results: In Republic o f  Moldova, Reocormon® is used for the treatment o f  anemia in chronic 
hemodialysis patients. Neither o f  the 47 patients examined had been treated with the necessary 
dosage and for the right period o f  time due to financial problems. Only 5 o f  the 47 patients have 
reached the recommended targeted hemoglobin level. This could be the result o f  an inadequate 
dosage, a poor control o f  iron levels or because o f  an associated chronic disease, such as a chronic 
inflammation o f  the kidney or the urinary tract.
Conclusions: Anemia is relative rare in the incipient stages o f  kidney disease (1-3 stages 
KDOQI). The prevalence o f  anemia starts to increase significantly when the glomerular filtrate rate < 60 
mL/min. Iron level should be checked before administrating an erythropoiesis-stimulating agent.
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Introduction: Obesity is the chronical polyetiological disease, which associated with some 
genetical and neurological factors, changes o f  functions o f  endocrine system, one o f  the serious 
factors o f  occurrence o f  diabetes II, essential hypertension, dyslipidemia, cardiovascular disease, 
reproductive disorders. In the basis o f  disorders o f  metabolic processes and occurrence o f  listed 
above conditions lying the resistance to insulin. Leptin has links with weight o f  adipose tissue, 
effect on insulinemia and resistance to insulin.
Aim of study: Analyze BMI, level o f  leptin, cholesterol and triglycerides in blood in patients 
with obesity (I, II, III lvl.) with components o f  metabolic syndrome, such as: diabetes II and 
essential hypertension.
Materials and methods: Since 2013 to 2014 we examine the 28 patients aged from 38 to 65 
years old (19 female and 9 male). In this group the 11 patients were ill with obesity o f  first level, 9 
patients - obesity o f  second level and 8 patients - obesity o f  third level. All patents were ill with 
moderate diabetes in phase o f  subcompensation. During the examination in all patients was the 
condition o f  metabolism o f  carbohydrate, lipid, protein, electrolyte and instrumental examination.
Discussion results: On the basis o f  examination, in the patients with obesity o f  first level, the 
BMI was 32,00 ± 0,38 kg\m2, level o f  leptin - 34,84 ± 6,40 ng\ml, level o f  cholesterol - 5,89 ± 0,31 
mmolM and level o f  triglycerides - 2,36 ± 0,9 mmolM. In the patients with obesity o f  second level, the 
BMI was 39,20 ±  0,49kg\m2, level o f  leptin - 35,48 ± 6,34ng\ml, level o f  cholesterol - 5,35 ± 
0,36mmol\l and level o f  triglycerides -  270 ± 0,41 mmolM. In the patients with obesity o f  third level, the
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